PER YEAR

HIGHSPEED
LINE FOR FILLING INSULIN CARTRIDGES


W H O : Civica is a non-profit generic drug company created to ensure a reliable supply of quality, affordable essential medicines.

W H A T : Civica Petersburg is a 140,000 square foot state-of-the-art manufacturing facility, established with \$100M federal support combined with private funding, to create a source of U.S.-made injectable medicines.

Along with products on the FDA drug shortages list, Civica will manufacture quality, affordable insulin. Civica will make the three types of insulin that account for the majority of insulin use in the United States (insulin glargine, lispro and aspart, corresponding to, and expected to be interchangeable with, the brand names products Lantus, Humalog and Novolog).

Civica is committed to offering all its products at the lowest sustainable price, without hidden rebates or discounts. Its insulins will be available to consumers at no more than \$30 per vial and $\$ 55$ for 5 pens - approximately a 90 percent reduction from current list prices. Civica's affordable insulin program is complementary to insulin provisions enacted in the Inflation Reduction Act.

Civica Petersburg has three manufacturing bays housing a vial line capable of filling 90 million vials per year, a syringe line that will make up to 50 million pre-filled syringes, and a high-speed line for filling insulin cartridges. Civica is developing dozens of generic drugs for manufacture in this facility and will be able to meet a substantial share of U.S. insulin demand.

Civica is also constructing a 50,000 sq ft quality laboratory in nearby Chesterfield County, made possible with support from the federal Economic Development Administration.

WHERE: The secure facility is located at 1 Civica Way, in Petersburg, Virginia, 20 minutes south of Richmond. The facility will bring $\mathbf{1 8 6}$ good paying jobs to this economically distressed community.

W HEN: Construction of the facility started in early 2021. The facility is substantially complete now, with filling operations to begin in the coming months and the first FDA approvals expected in 2024.

